The design of orally active iron chelators

Annals of the New York Academy of Sciences

Volumn 1054, Issue , 2005, Pages 141-154

  Hider, Robert C ^a   Zhou, Tao ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Chelation theory; Iron chelators; Nontransferrin bound iron (NTBI); Orally active chelators; Thaalassemia

Indexed keywords

CGP 5015; CGP 65015; CP 502; DEFERASIROX; DEFERIPRONE; DEFERITRIN; DEFEROXAMINE; DEFERRIFERRITHIOCIN; IRON CHELATING AGENT; PYRIDINE DERIVATIVE; SCAVENGER; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG DESIGN; DRUG EFFICACY; HUMAN; IRON CHELATION; IRON OVERLOAD; NEPHROTOXICITY; NEUTROPENIA; OXIDATION REDUCTION POTENTIAL; STRUCTURE ACTIVITY RELATION; SYSTEMIC DISEASE;

EID: 29744468975     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1345.017     Document Type: Conference Paper

References (21)

1. HERSHKO, C. et al. 2004. Purging iron from the heart. Brit. J. Haematol. 125: 545-551.
2. SHWEKY, I. et al. 1994. Syntheses, structures and magnetic properties of two dinuclear iron(III) citrate complexes. Inorg. Chem. 33: 5161-5162.
3. PIERRE, J.L. & I. GAUTIER-LUNEAU. 2000. Iron and citric acid: a fuzzy chemistry of ubiquitous biological relevance. Biometals 13: 91-96.
4. HIDER, R.C. 2002. Nature of non transferrin bound iron. Eur. J. Clin. Invest. 32: 50-52.
5. 3+ values. J. Med. Chem. 42: 4814-4823.
6. NICK, H. et al. 2003. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr. Med. Chem. 10: 1065-1076.
7. LOWTHER, N. et al. 1999. In vitro and in situ permeability of a "second generation" hydroxypyridinone oral iron chelator: correlation with physicochemical properties and oral activity. Pharm. Res. 16: 434-440.
8. LIPINSKI, C.A. et al. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 23: 3-25.
9. LIU, Z.D. & R.C. HIDER. 2002. Design of iron chelators with therapeutic application. Coord. Chem. Rev. 232: 151-171.
10. RYABUKIN, Y.I. et al. 1987. Synthesis and investigation of complex compounds of transition metals with di(-hydroxyphenyl)-1,2,4-oxadiazole and its 1,2,4-triazole analogues. Sov. J. Coord. Chem. (Engl. Transl.) 13: 493-499.
11. LIU, Z.D. & R.C. HIDER. 2002. Design of clinically useful iron(III)-selective chelators. Med. Res. Rev. 22: 26-64.
12. BERGERON, R.J. et al. 1994. The Deferrithiocin Pharmacophore. J. Med. Chem. 37: 1411-1417.
13. BERGERON, R.J. et al. 1999. Effects of C-4 stereochemistry and C-4′ hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues. J. Med. Chem. 42: 2432-2440.
14. PETER, H.H. 1985. Industrial aspects of iron chelators: pharmaceutical applications. In Proteins of Iron Storage and Transport. G. Spik, J. Montreuil, R.R. Crichton & J. Mazurier, Eds: 293-303. Elsevier. New York.
15. II. Eur. J. Inorg. Chem. 21: 4177-4192.
16. PORTER, J.B. et al. 1988. Iron mobilisation from hepatocytes monolayer cultures by chelators: the importance of membrane permeability and iron binding constant. Blood 72: 1497-1505.
17. HIDER, R.C. et al. 1990. The development of hydroxypyridin-4-ones as orally active iron chelators. Ann. N.Y. Acad. Sci. 612: 327-338.
18. MAGGIO, A. et al. 2002. Deferiprone versus deferoxamine in patients with thalassaemia major: a randomised clinical trial. Blood Cells Mol. & Dis. 28: 196-208.
19. ANDERSON, L.J. et al. 2002. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular functions in β-thalassaemia. Lancet 360: 516-520.
20. GRADY, R.W. & P.J. GIARDINA. 2000. Iron chelation: rationale for combination therapy. In Iron Chelators: New Development Strategies. D.G. Badman, R.J. Bergeron & G.M. Brittenham, Eds: 293-310. Saratoga. Ponte Vedra Beach, FL.
21. MOURAD, F.H. et al. 2003. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Brit. J. Haematol. 121: 187.